首页 > 最新文献

Journal of Diabetes最新文献

英文 中文
Associations of Stressful Life Events With Diabetes Incidence in China: Insights From the China Kadoorie Biobank 中国压力生活事件与糖尿病发病率的关系:来自中国嘉道理生物库的见解
IF 3.7 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-09-01 DOI: 10.1111/1753-0407.70149
Jing Qian, Huiying Cheng, Xuening Dai, Dianjianyi Sun, Pei Pei, Meng Wang, Yingjun Li

Background

Limited empirical evidence exists on the link between exposure to various stressful life events (SLEs) and the heightened risk of Diabetes Mellitus (DM) within the mainland Chinese population.

Methods

We conducted this prospective cohort study with 455,464 participants from the China Kadoorie Biobank (CKB); we examined associations between SLEs exposures and DM outcomes. We employed multivariable Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), adjusting for potential confounders.

Results

Over a median follow-up of 10.1 years, 14,218 DM cases were identified. A dose–response relationship was observed between the number of SLEs, personal-related events, and the risk of DM. The higher the number of SLEs experienced, the higher the risk of developing diabetes (HR = 1.06, 95% CI = 1.01–1.12); individuals who experienced personal-related events had a higher risk of developing DM (HR = 1.17, 95% CI = 1.01–1.36), and those who experienced marital separation/divorce had a 53% increased risk of DM (HR = 1.53, 95% CI = 1.12–2.09). Subgroup analyses revealed effect modifications based on birth cohort, sex, and area.

Conclusion

By exploring the association of multiple SLEs with the development of DM, we identified marital separation/divorce as a driver of increased DM risk.

背景在中国大陆人群中,暴露于各种应激性生活事件(SLEs)与糖尿病(DM)风险升高之间的联系存在有限的经验证据。方法:我们对来自中国嘉道理生物库(CKB)的455,464名参与者进行了前瞻性队列研究;我们研究了SLEs暴露与糖尿病结局之间的关系。我们采用多变量Cox比例风险模型来估计风险比(hr)和95%置信区间(ci),并对潜在混杂因素进行调整。结果在10.1年的中位随访中,共发现14218例糖尿病病例。SLEs次数、个人相关事件与糖尿病风险之间存在剂量-反应关系。经历SLEs次数越多,发生糖尿病的风险越高(HR = 1.06, 95% CI = 1.01-1.12);经历过个人相关事件的人患糖尿病的风险更高(HR = 1.17, 95% CI = 1.01-1.36),经历过婚姻分居/离婚的人患糖尿病的风险增加53% (HR = 1.53, 95% CI = 1.12-2.09)。亚组分析显示基于出生队列、性别和地区的效果改变。结论:通过探索多重SLEs与糖尿病发展的关系,我们确定婚姻分居/离婚是糖尿病风险增加的驱动因素。
{"title":"Associations of Stressful Life Events With Diabetes Incidence in China: Insights From the China Kadoorie Biobank","authors":"Jing Qian,&nbsp;Huiying Cheng,&nbsp;Xuening Dai,&nbsp;Dianjianyi Sun,&nbsp;Pei Pei,&nbsp;Meng Wang,&nbsp;Yingjun Li","doi":"10.1111/1753-0407.70149","DOIUrl":"https://doi.org/10.1111/1753-0407.70149","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Limited empirical evidence exists on the link between exposure to various stressful life events (SLEs) and the heightened risk of Diabetes Mellitus (DM) within the mainland Chinese population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted this prospective cohort study with 455,464 participants from the China Kadoorie Biobank (CKB); we examined associations between SLEs exposures and DM outcomes. We employed multivariable Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), adjusting for potential confounders.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Over a median follow-up of 10.1 years, 14,218 DM cases were identified. A dose–response relationship was observed between the number of SLEs, personal-related events, and the risk of DM. The higher the number of SLEs experienced, the higher the risk of developing diabetes (HR = 1.06, 95% CI = 1.01–1.12); individuals who experienced personal-related events had a higher risk of developing DM (HR = 1.17, 95% CI = 1.01–1.36), and those who experienced marital separation/divorce had a 53% increased risk of DM (HR = 1.53, 95% CI = 1.12–2.09). Subgroup analyses revealed effect modifications based on birth cohort, sex, and area.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>By exploring the association of multiple SLEs with the development of DM, we identified marital separation/divorce as a driver of increased DM risk.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 9","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70149","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of GLP-1 Receptor Agonists on Suicide Behavior: A Meta-Analysis Based on Randomized Controlled Trials GLP-1受体激动剂对自杀行为的影响:基于随机对照试验的荟萃分析
IF 3.7 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-08-31 DOI: 10.1111/1753-0407.70151
Jingqi Chen, Qiufeng Zhang, Qingping Wu, Xiaoming Zhang, Zhiyi Xiang, Sidong Zhu, Tianfu Dai, Yuexiu Si

Background

This meta-analysis aims to assess the association between exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the incidence of suicidal behavior in patients with type 2 diabetes mellitus (T2DM)/obesity.

Methods

A comprehensive search of electronic databases, including PubMed, Web of Science, the Cochrane Library, and ClinicalTrials.gov, was conducted from the inception of the databases. The risk ratio (RR) and 95% confidence intervals (95% CI) were calculated.

Results

This meta-analysis included data from 25 randomized controlled trials (RCTs). The results indicated no significant difference in the incidence of suicidal behavior between the GLP-1 RA exposure group and the control group (RR = 0.84, 95% CI: 0.54–1.32, p = 0.46, I2 = 0%). Subgroup analysis showed no significant differences in the incidence of suicidal behavior among participants with T2DM (RR = 0.74), obesity (RR = 1.07), adolescents (RR = 0.91), and adults (RR = 0.84). Additionally, no significant differences were observed between the two groups in any type of suicidal behavior, including suicidal ideation (RR = 1.04), suicide attempts (RR = 0.68), depression-related suicides (RR = 0.65), and completed suicides (RR = 1.06). There were also no significant differences between the groups for any type of GLP-1 RA, including dulaglutide (RR = 0.46), exenatide (RR = 0.98), semaglutide (RR = 0.82), lixisenatide (RR = 1.25), and liraglutide (RR = 0.92). No significant differences were observed between the exposure group and control group according to different comparators, including placebo (RR = 0.91) and others (RR = 1.08). All subgroup analyses showed p-values greater than 0.05 (two-sided tests) and I2 values of 0%.

Conclusion

Our findings suggest that there is no significant association between GLP-1 RA exposure and suicidal behaviors in patients with T2DM or obesity.

本荟萃分析旨在评估2型糖尿病(T2DM)/肥胖患者暴露于胰高血糖素样肽-1受体激动剂(GLP-1 RAs)与自杀行为发生率之间的关系。方法从数据库建立之初,对PubMed、Web of Science、Cochrane Library和ClinicalTrials.gov等电子数据库进行全面检索。计算风险比(RR)和95%置信区间(95% CI)。结果本荟萃分析纳入了25项随机对照试验(rct)的数据。结果显示,GLP-1 RA暴露组与对照组自杀行为发生率无显著差异(RR = 0.84, 95% CI: 0.54 ~ 1.32, p = 0.46, I2 = 0%)。亚组分析显示,T2DM (RR = 0.74)、肥胖(RR = 1.07)、青少年(RR = 0.91)和成人(RR = 0.84)的自杀行为发生率无显著差异。此外,两组在自杀意念(RR = 1.04)、自杀企图(RR = 0.68)、抑郁相关自杀(RR = 0.65)和自杀完成(RR = 1.06)等任何类型的自杀行为方面均无显著差异。各组间GLP-1 RA的差异无统计学意义,包括杜拉鲁肽(RR = 0.46)、艾塞那肽(RR = 0.98)、semaglutide (RR = 0.82)、利昔那肽(RR = 1.25)和利拉鲁肽(RR = 0.92)。不同比较物,包括安慰剂组(RR = 0.91)和其他比较物(RR = 1.08),暴露组与对照组之间无显著差异。所有亚组分析显示p值大于0.05(双侧检验),I2值为0%。结论我们的研究结果表明GLP-1 RA暴露与T2DM或肥胖患者的自杀行为之间没有显著相关性。
{"title":"Impact of GLP-1 Receptor Agonists on Suicide Behavior: A Meta-Analysis Based on Randomized Controlled Trials","authors":"Jingqi Chen,&nbsp;Qiufeng Zhang,&nbsp;Qingping Wu,&nbsp;Xiaoming Zhang,&nbsp;Zhiyi Xiang,&nbsp;Sidong Zhu,&nbsp;Tianfu Dai,&nbsp;Yuexiu Si","doi":"10.1111/1753-0407.70151","DOIUrl":"https://doi.org/10.1111/1753-0407.70151","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This meta-analysis aims to assess the association between exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the incidence of suicidal behavior in patients with type 2 diabetes mellitus (T2DM)/obesity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A comprehensive search of electronic databases, including PubMed, Web of Science, the Cochrane Library, and ClinicalTrials.gov, was conducted from the inception of the databases. The risk ratio (RR) and 95% confidence intervals (95% CI) were calculated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>This meta-analysis included data from 25 randomized controlled trials (RCTs). The results indicated no significant difference in the incidence of suicidal behavior between the GLP-1 RA exposure group and the control group (RR = 0.84, 95% CI: 0.54–1.32, <i>p</i> = 0.46, <i>I</i><sup>2</sup> = 0%). Subgroup analysis showed no significant differences in the incidence of suicidal behavior among participants with T2DM (RR = 0.74), obesity (RR = 1.07), adolescents (RR = 0.91), and adults (RR = 0.84). Additionally, no significant differences were observed between the two groups in any type of suicidal behavior, including suicidal ideation (RR = 1.04), suicide attempts (RR = 0.68), depression-related suicides (RR = 0.65), and completed suicides (RR = 1.06). There were also no significant differences between the groups for any type of GLP-1 RA, including dulaglutide (RR = 0.46), exenatide (RR = 0.98), semaglutide (RR = 0.82), lixisenatide (RR = 1.25), and liraglutide (RR = 0.92). No significant differences were observed between the exposure group and control group according to different comparators, including placebo (RR = 0.91) and others (RR = 1.08). All subgroup analyses showed <i>p</i>-values greater than 0.05 (two-sided tests) and <i>I</i><sup>2</sup> values of 0%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our findings suggest that there is no significant association between GLP-1 RA exposure and suicidal behaviors in patients with T2DM or obesity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 9","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70151","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to Commentary on “Sleep Phenotypes, Genetic Susceptibility, and Risk of Obesity in Patients With Type 2 Diabetes: A National Prospective Cohort Study” 对《2型糖尿病患者睡眠表型、遗传易感性和肥胖风险:一项全国前瞻性队列研究》评论的回应
IF 3.7 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-08-23 DOI: 10.1111/1753-0407.70145
Lei Xi, Juan Shi, Ying Peng, Yifei Zhang, Yanan Cao, Weiqing Wang

We thank the authors for their insightful comments and for recognizing that our manuscript provides valuable details about behavioral and genetic factors affecting the risk of obesity in people with type 2 diabetes (T2D) [1].

Firstly, as mentioned in our article, there may be recall bias based on patient self-reported sleep duration, and objectively measuring habitual sleep duration using actigraphy can provide more reliable data. However, considering its simplicity, practicality, and correlation with instrument measurement results, patients' self-reported sleep duration is still internationally recognized and widely used in population-based studies [2, 3].

Secondly, the relationship between sleep, diabetes and obesity is really complex and challenging. As mentioned by the authors, most exploratory experiments on sleep are temporary, especially for sleep deprivation. There are interactions among sleep, diabetes and obesity that impact cardiovascular and metabolic health, just like the intertwined trio. To avoid the potential impact of sleep related diseases, we excluded patients who reported implausible values of sleep duration (i.e., < 3 or > 12 h/night), use of sleeping aids, or psychiatric medications at baseline. It should be pointed out that the above efforts cannot completely eliminate the potential impact of sleep disorders on our study results, and how to reduce their potential effects is also one of the key considerations in our future research. The Pittsburgh Sleep Quality Index (PSQI) and the Epworth Sleepiness Scale (ESS) are indeed effective tools.

As we mentioned in the article, we acknowledge that “although we have adjusted for several covariates, there are potential confounders that could influence the results, such as dietary habits, physical activity, socioeconomic biases, and glucose-lowering medications, which we did not include in this study, and further research is needed to strengthen our understanding of these complex associations”, when it comes to both clinical and genetic analysis. In addition, a more complex and precise polygenic risk score (PRS) model for body mass index (BMI) is also under consideration.

In conclusion, we thank the authors for the wise and valuable comments and suggestions. We hope these clarifications address the issues raised and we intend to use more complex and appropriate models to explore their associations in future research.

The authors declare no conflicts of interest.

我们感谢作者的深刻见解,并承认我们的论文提供了影响2型糖尿病(T2D)患者肥胖风险的行为和遗传因素的有价值的细节。首先,正如我们在文章中提到的,基于患者自我报告的睡眠时间可能存在回忆偏差,使用活动描记仪客观测量习惯性睡眠时间可以提供更可靠的数据。然而,考虑到患者自我报告睡眠时间的简单、实用以及与仪器测量结果的相关性,患者自我报告睡眠时间仍然是国际上公认的,并被广泛应用于基于人群的研究[2,3]。其次,睡眠、糖尿病和肥胖之间的关系非常复杂和具有挑战性。正如作者所提到的,大多数关于睡眠的探索性实验都是暂时的,尤其是对睡眠剥夺的实验。睡眠、糖尿病和肥胖之间存在相互作用,影响心血管和代谢健康,就像交织在一起的三重奏一样。为了避免睡眠相关疾病的潜在影响,我们排除了在基线时报告睡眠持续时间(即每晚3或12小时)、使用助眠剂或精神药物的患者。需要指出的是,上述努力并不能完全消除睡眠障碍对我们研究结果的潜在影响,如何降低其潜在影响也是我们未来研究的重点考虑之一。匹兹堡睡眠质量指数(PSQI)和爱普沃斯嗜睡量表(ESS)确实是有效的工具。正如我们在文章中提到的,我们承认“尽管我们已经调整了几个协变量,但仍有可能影响结果的潜在混杂因素,如饮食习惯、体育活动、社会经济偏见和降糖药物,我们没有将其纳入本研究,需要进一步的研究来加强我们对这些复杂关联的理解”,当涉及到临床和遗传分析时。此外,一种更为复杂和精确的体重指数(BMI)多基因风险评分(PRS)模型也在考虑之中。最后,我们感谢作者提出的明智而宝贵的意见和建议。我们希望这些澄清能解决所提出的问题,我们打算在未来的研究中使用更复杂和合适的模型来探索它们之间的联系。作者声明无利益冲突。
{"title":"Response to Commentary on “Sleep Phenotypes, Genetic Susceptibility, and Risk of Obesity in Patients With Type 2 Diabetes: A National Prospective Cohort Study”","authors":"Lei Xi,&nbsp;Juan Shi,&nbsp;Ying Peng,&nbsp;Yifei Zhang,&nbsp;Yanan Cao,&nbsp;Weiqing Wang","doi":"10.1111/1753-0407.70145","DOIUrl":"https://doi.org/10.1111/1753-0407.70145","url":null,"abstract":"<p>We thank the authors for their insightful comments and for recognizing that our manuscript provides valuable details about behavioral and genetic factors affecting the risk of obesity in people with type 2 diabetes (T2D) [<span>1</span>].</p><p>Firstly, as mentioned in our article, there may be recall bias based on patient self-reported sleep duration, and objectively measuring habitual sleep duration using actigraphy can provide more reliable data. However, considering its simplicity, practicality, and correlation with instrument measurement results, patients' self-reported sleep duration is still internationally recognized and widely used in population-based studies [<span>2, 3</span>].</p><p>Secondly, the relationship between sleep, diabetes and obesity is really complex and challenging. As mentioned by the authors, most exploratory experiments on sleep are temporary, especially for sleep deprivation. There are interactions among sleep, diabetes and obesity that impact cardiovascular and metabolic health, just like the intertwined trio. To avoid the potential impact of sleep related diseases, we excluded patients who reported implausible values of sleep duration (i.e., &lt; 3 or &gt; 12 h/night), use of sleeping aids, or psychiatric medications at baseline. It should be pointed out that the above efforts cannot completely eliminate the potential impact of sleep disorders on our study results, and how to reduce their potential effects is also one of the key considerations in our future research. The Pittsburgh Sleep Quality Index (PSQI) and the Epworth Sleepiness Scale (ESS) are indeed effective tools.</p><p>As we mentioned in the article, we acknowledge that “although we have adjusted for several covariates, there are potential confounders that could influence the results, such as dietary habits, physical activity, socioeconomic biases, and glucose-lowering medications, which we did not include in this study, and further research is needed to strengthen our understanding of these complex associations”, when it comes to both clinical and genetic analysis. In addition, a more complex and precise polygenic risk score (PRS) model for body mass index (BMI) is also under consideration.</p><p>In conclusion, we thank the authors for the wise and valuable comments and suggestions. We hope these clarifications address the issues raised and we intend to use more complex and appropriate models to explore their associations in future research.</p><p>The authors declare no conflicts of interest.</p>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 8","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70145","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144891692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Update on GLP-1 Receptor Agonists GLP-1受体激动剂的最新进展
IF 3.7 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-08-22 DOI: 10.1111/1753-0407.70147
Zachary Bloomgarden

The glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are a class of medications primarily developed for the management of type 2 diabetes (T2D) and are increasingly being used for various other health effects. Here's a simplified overview of their history, effects, and future prospects:

Glucose-dependent insulinotropic polypeptide (GIP) and then GLP-1 were identified in the 1970s as peptides potentiating the insulin secretory response to nutrient ingestion. In the early 1980s, the proglucagon amino acid sequence and gene were mapped, leading to the recognition of the common derivation of GLP-1 and GLP-2, produced in the L-cells of the distal small intestine, while GIP is produced in the K-cells of the proximal small intestine. The first therapeutically used GLP-1RA was isolated as exendin-4 from the saliva of a venomous lizard, Heloderma suspectum (the “Gila monster”), in 1992, with initial preclinical studies reported in 1996; although FDA approval for its use in treatment of T2D as exenatide was not granted until 2005. The next GLP-1RA used therapeutically was liraglutide, receiving approval in 2010, with dulaglutide receiving approval in 2014, semaglutide approval in 2017, and tirzepatide (a combined agonist of GLP-1 and GIP) approval in 2022; FDA approvals of liraglutide, semaglutide, and tirzepatide for treatment of obesity were granted in 2014, 2021, and 2023, respectively.

Both the GLP-1 and GIP receptor agonists enhance insulin production when glucose levels are elevated. This physiological insulin-secretory effect contrasts with the action of the older sulfonylureas, which activate the ATP-sensitive potassium channels of the pancreatic beta cells, mimicking the cellular process that physiologically acts to link insulin production to the beta cell's energy state. The consequent increase in endogenous insulin production leads the GLP-1RAs to have glucose-lowering action comparable to that of daily treatment with basal insulin [1]; with weight loss rather than weight gain and with lower likelihood of hypoglycemia [2, 3].

In addition to their glycemic benefits, GLP-1RAs are associated with improvement in mortality and in CV and renal outcomes in clinical trials [4, 5], both in people having and not having T2D [6], as well as in real-world studies of people with T2D [7] and of people with obesity without T2D [8]. In a study from the US Veteran's Affairs hospitals with mean followup of nearly 4 years comparing more than 200 000 persons receiving GLP-1RA with more than 1.2 million receiving usual care, benefits of GLP-1RAs included reduction in risk of stroke, myocardial infarction, pulmonary embolism, phlebitis, heart failure, hepatic failure, chronic kidney disease, bacterial infections, postprocedural respiratory complications, aspiration pneumonitis, chronic obstructive pulmonary disease, pneumonia and respiratory failure, a

人们对GLP-1RAs与其他糖尿病药物,特别是SGLT2抑制剂联合使用的兴趣越来越大。这种组合似乎增强了心血管和肾脏健康,显示出与单独使用GLP-1RA的个体相比,心力衰竭和死亡率的风险更低。新兴研究表明,GLP-1RAs可能预防神经退行性疾病,包括阿尔茨海默病[15]和帕金森病[16],并对认知功能[17]产生有益影响;尽管其中一些可能只是反映了与glp - 1ra相关的中风减少。代谢相关的脂肪性肝病影响全球约三分之二的T2D患者,其中三分之二患有脂肪性肝炎,多项研究显示GLP-1RA对糖尿病和非糖尿病患者的益处[18,19]。GLP-1RAs与阻塞性睡眠呼吸暂停患者呼吸暂停低通气指数的降低有关,替西肽在这方面似乎更有效。GLP-1RA配方的创新包括口服选择和针对GIP、胰高血糖素、胰胰肽以及GLP-1的双作用和三作用药物,用于葡萄糖和体重管理。新药和生物仿制药正在测试中。口服活性GLP-1RAs与肠外给药GLP-1RAs具有相似的代谢、减肥和cv保护作用,尽管效力较弱。类似于“他汀假说”,他汀类药物与其降胆固醇效果成正比,可以预防或治疗心血管疾病,我们似乎接近于确认“GLP-1RA假说”,即这类扩展的药物可以预防或治疗心血管疾病,在一定程度上与其降体重和降血糖效果成正比,并具有多种额外的益处。然而,我们在这些药物上的成功也导致了一个两难的局面:全世界有近2亿人患有T2D和高心血管疾病风险。我们如何确保这些有效但非常昂贵的药物能够由我们现在认识的所有患者负担得起?作者声明无利益冲突。
{"title":"An Update on GLP-1 Receptor Agonists","authors":"Zachary Bloomgarden","doi":"10.1111/1753-0407.70147","DOIUrl":"https://doi.org/10.1111/1753-0407.70147","url":null,"abstract":"<p>The glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are a class of medications primarily developed for the management of type 2 diabetes (T2D) and are increasingly being used for various other health effects. Here's a simplified overview of their history, effects, and future prospects:</p><p>Glucose-dependent insulinotropic polypeptide (GIP) and then GLP-1 were identified in the 1970s as peptides potentiating the insulin secretory response to nutrient ingestion. In the early 1980s, the proglucagon amino acid sequence and gene were mapped, leading to the recognition of the common derivation of GLP-1 and GLP-2, produced in the L-cells of the distal small intestine, while GIP is produced in the K-cells of the proximal small intestine. The first therapeutically used GLP-1RA was isolated as exendin-4 from the saliva of a venomous lizard, <i>Heloderma suspectum</i> (the “Gila monster”), in 1992, with initial preclinical studies reported in 1996; although FDA approval for its use in treatment of T2D as exenatide was not granted until 2005. The next GLP-1RA used therapeutically was liraglutide, receiving approval in 2010, with dulaglutide receiving approval in 2014, semaglutide approval in 2017, and tirzepatide (a combined agonist of GLP-1 and GIP) approval in 2022; FDA approvals of liraglutide, semaglutide, and tirzepatide for treatment of obesity were granted in 2014, 2021, and 2023, respectively.</p><p>Both the GLP-1 and GIP receptor agonists enhance insulin production when glucose levels are elevated. This physiological insulin-secretory effect contrasts with the action of the older sulfonylureas, which activate the ATP-sensitive potassium channels of the pancreatic beta cells, mimicking the cellular process that physiologically acts to link insulin production to the beta cell's energy state. The consequent increase in endogenous insulin production leads the GLP-1RAs to have glucose-lowering action comparable to that of daily treatment with basal insulin [<span>1</span>]; with weight loss rather than weight gain and with lower likelihood of hypoglycemia [<span>2, 3</span>].</p><p>In addition to their glycemic benefits, GLP-1RAs are associated with improvement in mortality and in CV and renal outcomes in clinical trials [<span>4, 5</span>], both in people having and not having T2D [<span>6</span>], as well as in real-world studies of people with T2D [<span>7</span>] and of people with obesity without T2D [<span>8</span>]. In a study from the US Veteran's Affairs hospitals with mean followup of nearly 4 years comparing more than 200 000 persons receiving GLP-1RA with more than 1.2 million receiving usual care, benefits of GLP-1RAs included reduction in risk of stroke, myocardial infarction, pulmonary embolism, phlebitis, heart failure, hepatic failure, chronic kidney disease, bacterial infections, postprocedural respiratory complications, aspiration pneumonitis, chronic obstructive pulmonary disease, pneumonia and respiratory failure, a","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 8","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70147","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144888188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association Between Serum Advanced Glycation End Products and Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A 3-Year Longitudinal Cohort Study (2019–2022) 血清晚期糖基化终产物与心血管-肾-代谢(CKM)综合征的相关性:一项为期3年的纵向队列研究(2019-2022)
IF 3.7 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-08-21 DOI: 10.1111/1753-0407.70137
Hui Zhao, Ze-wen Zhang, Tao Luo, Dilihumaer Aili, Wen-huan Ding, Yuan-yuan Li, Yuan-sheng Gu, Shulipan Aslibek, Jing-jing He, Wen-hui Yu, Run-ze Ma, Anaer Gaoshao, Ting-ting Qiao, Guo-zhen Zhang, Henry S. Lynn, Mu-long Du, Jiang-hong Dai

Background

Cardiovascular-kidney-metabolic (CKM) syndrome begins with obesity and glucose abnormalities, advancing to cardiovascular and kidney complications. This study investigates the relationship of advanced glycation end products (AGEs) with CKM syndrome staging and transition patterns.

Methods

This 3-year longitudinal study (2019–2022) of 1264 adults identified five CKM trajectory groups: Group 1 (stable low-risk, 6.7%, stage 0/1), Group 2 (fluctuating, 15.8%, stages 0/1–2), Group 3 (stable intermediate, 52.8%, stage 2), Group 4 (progressors, 8.9%, to stage 3/4), and Group 5 (stable high-risk, 15.8%, stage 3/4), from baseline distributions of stage 0 (1.6%), 1 (12.3%), 2 (71.0%), 3 (5.8%), and 4 (9.2%). Serum AGEs were quantified by UPLC-MS/MS.

Results

Higher AGEs levels showed significant associations with CKM severity, with each 1-SD increase corresponding to a 30% greater likelihood of advanced staging (95% CI:10%–54%). Quartile analysis revealed a dose–response relationship (Q2:1.66[1.15–2.41]; Q3:1.67[1.12–2.48]; Q4:1.92[1.31–2.81]). Longitudinally, the total AGEs score was significantly associated with CKM transition patterns from 2019 to 2022. The odds ratios (ORs) for Group 2, Group 3, Group 4, and Group 5 compared to Group 1 were 1.61 (1.06–2.45), 1.64 (1.11–2.41), 1.71 (1.07–2.73), and 2.03 (1.32–3.13), respectively.

Conclusions

These findings suggest that serum AGEs are linked to CKM severity and progression, potentially serving as biomarkers for CKM staging and targets for intervention.

心血管-肾脏代谢综合征(CKM)始于肥胖和血糖异常,发展为心血管和肾脏并发症。本研究探讨晚期糖基化终产物(AGEs)与CKM综合征分期和过渡模式的关系。方法这项为期3年(2019-2022)的1264名成年人的纵向研究确定了5个CKM轨迹组:组1(稳定低风险,6.7%,0/1期)、组2(波动,15.8%,0/1 - 2期)、组3(稳定中等,52.8%,2期)、组4(进展,8.9%,至3/4期)和组5(稳定高风险,15.8%,3/4期),从0期(1.6%)、1期(12.3%)、2期(71.0%)、3期(5.8%)和4期(9.2%)的基线分布。采用UPLC-MS/MS法测定血清AGEs。结果较高的AGEs水平与CKM严重程度显著相关,每增加1-SD,晚期的可能性增加30% (95% CI: 10%-54%)。四分位数分析显示剂量-反应关系(Q2:1.66[1.15-2.41]; q2:1.67[1.12-2.48]; q2:1.92[1.31-2.81])。纵向上,AGEs总分与2019 - 2022年CKM转变模式显著相关。组2、组3、组4、组5与组1的比值比(or)分别为1.61(1.06-2.45)、1.64(1.11-2.41)、1.71(1.07-2.73)、2.03(1.32-3.13)。这些研究结果表明,血清AGEs与CKM的严重程度和进展有关,可能作为CKM分期和干预目标的生物标志物。
{"title":"Association Between Serum Advanced Glycation End Products and Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A 3-Year Longitudinal Cohort Study (2019–2022)","authors":"Hui Zhao,&nbsp;Ze-wen Zhang,&nbsp;Tao Luo,&nbsp;Dilihumaer Aili,&nbsp;Wen-huan Ding,&nbsp;Yuan-yuan Li,&nbsp;Yuan-sheng Gu,&nbsp;Shulipan Aslibek,&nbsp;Jing-jing He,&nbsp;Wen-hui Yu,&nbsp;Run-ze Ma,&nbsp;Anaer Gaoshao,&nbsp;Ting-ting Qiao,&nbsp;Guo-zhen Zhang,&nbsp;Henry S. Lynn,&nbsp;Mu-long Du,&nbsp;Jiang-hong Dai","doi":"10.1111/1753-0407.70137","DOIUrl":"https://doi.org/10.1111/1753-0407.70137","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cardiovascular-kidney-metabolic (CKM) syndrome begins with obesity and glucose abnormalities, advancing to cardiovascular and kidney complications. This study investigates the relationship of advanced glycation end products (AGEs) with CKM syndrome staging and transition patterns.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This 3-year longitudinal study (2019–2022) of 1264 adults identified five CKM trajectory groups: Group 1 (stable low-risk, 6.7%, stage 0/1), Group 2 (fluctuating, 15.8%, stages 0/1–2), Group 3 (stable intermediate, 52.8%, stage 2), Group 4 (progressors, 8.9%, to stage 3/4), and Group 5 (stable high-risk, 15.8%, stage 3/4), from baseline distributions of stage 0 (1.6%), 1 (12.3%), 2 (71.0%), 3 (5.8%), and 4 (9.2%). Serum AGEs were quantified by UPLC-MS/MS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Higher AGEs levels showed significant associations with CKM severity, with each 1-SD increase corresponding to a 30% greater likelihood of advanced staging (95% CI:10%–54%). Quartile analysis revealed a dose–response relationship (Q2:1.66[1.15–2.41]; Q3:1.67[1.12–2.48]; Q4:1.92[1.31–2.81]). Longitudinally, the total AGEs score was significantly associated with CKM transition patterns from 2019 to 2022. The odds ratios (ORs) for Group 2, Group 3, Group 4, and Group 5 compared to Group 1 were 1.61 (1.06–2.45), 1.64 (1.11–2.41), 1.71 (1.07–2.73), and 2.03 (1.32–3.13), respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings suggest that serum AGEs are linked to CKM severity and progression, potentially serving as biomarkers for CKM staging and targets for intervention.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 8","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70137","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144885052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Supplementing Inosine to Blood Collection Tubes Adds a Glycolytic Inhibitory Effect 向采血管补充肌苷增加糖酵解抑制作用
IF 3.7 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-08-20 DOI: 10.1111/1753-0407.70144
Yukio Kume, Motohiro Ohkubo, Naru NaKatuka, Sayaka Aritake-Okada, Teruhiko Yoshida, Hideaki Isago, Makoto Kurano
<p>At present, sodium fluoride (NaF)-supplemented tubes are used as usual blood collection tubes that can measure glucose and glycated hemoglobin (HbA1c) simultaneously. However, blood collection with NaF tubes show a decrease in glucose levels at room temperature within 4 h after blood collection [<span>1</span>]. The American Diabetes Association (ADA) guidelines recommend immersion of blood samples collected with heparin-lithium (Hp-Li) in ice water within 30 min or the use of tubes containing NaF and citrate buffer (FC) [<span>2</span>]. However, immediate immersion in ice water is difficult in clinical practice and citric acid is difficult to dissolve and is not suitable for HbA1c measurements because of hemolysis. Therefore, we aimed to develop blood collection tubes that are easier for clinical use than FC tubes and minimize blood glucose decline, compared with NaF tubes.</p><p>We collected 2 mL of whole blood each tube. Immediately after blood collection, each tube was agitated on a mix rotator at 3000 rpm (1470 g) for 5 min and then stored under storage conditions until immediately before measurement. The aliquoted blood collection tubes were stored at room temperature (25°C) or refrigerated (4°C). Then, the aliquoted whole blood was plasma-separated by centrifugation immediately and 2, 4, 24, and 48 h after collection. Glucose was measured immediately after separation, as well as HbA1c.</p><p>Changes in blood glucose levels in the NaF, FI, and FC tubes are shown in Figure 1A–D. Blood glucose changes were significantly attenuated to a greater degree in FI tubes than in NaF tubes at 4°C and 25°C conditions 4 and 24 h after sampling, whereas the blood glucose-preserving abilities of FI tubes were significantly inferior to those of FC tubes, except the case when stored at 4°C for 4 h. Regarding the criteria required from ADA (within 6.1% of the baseline blood glucose levels), the storage of FI blood collection tubes at 4°C did not reduce blood glucose levels by > 6.1%, which is the criteria required from ADA, in any sample up to 48 h, whereas the storage of FI blood collection tubes at room temperature reduced blood glucose levels by > 6.1% in 1 of 10 cases after 24 h (Figure S2), which were much superior to the NF tubes (Figures S1 and S2).</p><p>In addition, the enzymatic and immunoassay methods showed a significant difference with a <i>p</i> value of 0.005 in FC blood tubes, whereas no significant difference was observed for the FI blood tubes (Figure 1E,E). Concordantly, no significant difference in hemolytic Hb levels was observed in the NaF and FI tubes, but not in FC tubes, compared with Hp-Li tubes (Figure S4).</p><p>Regarding the mechanism, although the detail mechanisms will be published somewhere else, the inhibitory effects on ATP and glucose uptake decline in erythrocytes were considered. We believe that inosine addition to the NaF blood collection tube would contribute to measuring the blood glucose levels exactly, witho
目前常用的采血管采用氟化钠(NaF)补充管,可同时测量血糖和糖化血红蛋白(HbA1c)。然而,NaF管采血显示,采血后4小时内,室温下血糖水平下降。美国糖尿病协会(ADA)指南建议用肝素-锂(Hp-Li)采集的血液样本在冰水中浸泡30分钟或使用含有NaF和柠檬酸缓冲液(FC)[2]的管。然而,在临床实践中,立即浸泡在冰水中是困难的,柠檬酸难以溶解,由于溶血,不适合用于HbA1c的测量。因此,我们的目标是开发比FC管更易于临床使用的采血管,与NaF管相比,将血糖下降降到最低。每管取全血2ml。采集血液后,立即将每根试管在混合旋转器上以3000 rpm (1470 g)搅拌5分钟,然后在储存条件下保存至立即测量前。引用的采血管保存于室温(25℃)或冷藏(4℃)。然后,立即和采集后2、4、24、48 h进行离心血浆分离。分离后立即测量葡萄糖和HbA1c。NaF、FI和FC管的血糖水平变化如图1A-D所示。在4°C和25°C条件下,采样后4和24 h, FI管的血糖变化明显比NaF管减弱的程度更大,而FI管的血糖保存能力明显不如FC管,但在4°C保存4小时的情况除外。有关标准要求ADA(在6.1%的基线血糖水平),存储FI血液采集管在4°C没有降低血糖水平在6.1%,这是艾达的标准要求,在任何样本48 h,而FI血液采集管的存储在室温下血糖水平减少了在24小时后10例1的6.1%(图S2),这是优于NF管(图S1和S2)。此外,酶法和免疫法在FC血管中差异显著,p值为0.005,而在FI血管中差异不显著(图1E,E)。同样,与Hp-Li管相比,NaF和FI管中溶血Hb水平无显著差异,而FC管中则无显著差异(图S4)。关于其作用机制,虽然详细的机制将在其他地方发表,但考虑了对红细胞ATP和葡萄糖摄取下降的抑制作用。我们认为,在NaF采血管中加入肌苷将有助于准确测量血糖水平,而不会干扰HbA1c的测量。M.K.设计了这项研究。M.K.监督了这项研究。y.k., m.o., n.n.和M.K.进行了这项研究。Y.K.写了手稿。S.A.-O。, t.y., h.i.和M.K.审阅了手稿草稿。所有作者都对本文的全部内容负责,并已同意提交。本研究经东京大学医学研究生院伦理委员会批准(批准号:2020063 ni)。健康参与者提供书面知情同意书。作者声明无利益冲突。
{"title":"Supplementing Inosine to Blood Collection Tubes Adds a Glycolytic Inhibitory Effect","authors":"Yukio Kume,&nbsp;Motohiro Ohkubo,&nbsp;Naru NaKatuka,&nbsp;Sayaka Aritake-Okada,&nbsp;Teruhiko Yoshida,&nbsp;Hideaki Isago,&nbsp;Makoto Kurano","doi":"10.1111/1753-0407.70144","DOIUrl":"https://doi.org/10.1111/1753-0407.70144","url":null,"abstract":"&lt;p&gt;At present, sodium fluoride (NaF)-supplemented tubes are used as usual blood collection tubes that can measure glucose and glycated hemoglobin (HbA1c) simultaneously. However, blood collection with NaF tubes show a decrease in glucose levels at room temperature within 4 h after blood collection [&lt;span&gt;1&lt;/span&gt;]. The American Diabetes Association (ADA) guidelines recommend immersion of blood samples collected with heparin-lithium (Hp-Li) in ice water within 30 min or the use of tubes containing NaF and citrate buffer (FC) [&lt;span&gt;2&lt;/span&gt;]. However, immediate immersion in ice water is difficult in clinical practice and citric acid is difficult to dissolve and is not suitable for HbA1c measurements because of hemolysis. Therefore, we aimed to develop blood collection tubes that are easier for clinical use than FC tubes and minimize blood glucose decline, compared with NaF tubes.&lt;/p&gt;&lt;p&gt;We collected 2 mL of whole blood each tube. Immediately after blood collection, each tube was agitated on a mix rotator at 3000 rpm (1470 g) for 5 min and then stored under storage conditions until immediately before measurement. The aliquoted blood collection tubes were stored at room temperature (25°C) or refrigerated (4°C). Then, the aliquoted whole blood was plasma-separated by centrifugation immediately and 2, 4, 24, and 48 h after collection. Glucose was measured immediately after separation, as well as HbA1c.&lt;/p&gt;&lt;p&gt;Changes in blood glucose levels in the NaF, FI, and FC tubes are shown in Figure 1A–D. Blood glucose changes were significantly attenuated to a greater degree in FI tubes than in NaF tubes at 4°C and 25°C conditions 4 and 24 h after sampling, whereas the blood glucose-preserving abilities of FI tubes were significantly inferior to those of FC tubes, except the case when stored at 4°C for 4 h. Regarding the criteria required from ADA (within 6.1% of the baseline blood glucose levels), the storage of FI blood collection tubes at 4°C did not reduce blood glucose levels by &gt; 6.1%, which is the criteria required from ADA, in any sample up to 48 h, whereas the storage of FI blood collection tubes at room temperature reduced blood glucose levels by &gt; 6.1% in 1 of 10 cases after 24 h (Figure S2), which were much superior to the NF tubes (Figures S1 and S2).&lt;/p&gt;&lt;p&gt;In addition, the enzymatic and immunoassay methods showed a significant difference with a &lt;i&gt;p&lt;/i&gt; value of 0.005 in FC blood tubes, whereas no significant difference was observed for the FI blood tubes (Figure 1E,E). Concordantly, no significant difference in hemolytic Hb levels was observed in the NaF and FI tubes, but not in FC tubes, compared with Hp-Li tubes (Figure S4).&lt;/p&gt;&lt;p&gt;Regarding the mechanism, although the detail mechanisms will be published somewhere else, the inhibitory effects on ATP and glucose uptake decline in erythrocytes were considered. We believe that inosine addition to the NaF blood collection tube would contribute to measuring the blood glucose levels exactly, witho","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 8","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70144","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144869592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First-Degree Family History of Diabetes Is Associated With the Presence of Depressive Symptoms Independent of Lifestyle Risk Factors and Cardiometabolic Risk Factors 糖尿病一级家族史与抑郁症状的存在相关,独立于生活方式危险因素和心脏代谢危险因素
IF 3.7 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-08-17 DOI: 10.1111/1753-0407.70139
Mengying Chen, Huimin Xia, Yaohui Yu, Yuhua Wang, Wei Chen, Enyu Lou, Zhezhe Tang, Lijuan Yang, Shengjie Ge, Bo Yang, Xuejiang Gu, Xiang Hu

Background

Co-occurrence of depression and diabetes is a prototypical example of mental-physical comorbidity. This study aims to investigate the association between first-degree family history of diabetes (FHD) and the presence of depressive symptoms.

Methods

The present work was one part of the baseline survey from the REACTION study. First-degree FHD was defined as having one or more first-degree relatives with diabetes. The Patient Health Questionnaire-9 was administered to detect the presence of depressive symptoms with its score ≥ 5. Logistic regression analyses were performed to determine the association between first-degree FHD and the presence of depressive symptoms.

Results

A total of 4804 participants were enrolled in the present study. Individuals with first-degree FHD were more likely to suffer from depressive symptoms compared with those without first-degree FHD (7.2% versus 4.9%, p = 0.004). The odds ratio (OR) of depressive symptoms was increased by 49.8% with the presence of first-degree FHD after adjustment of gender, age, socioeconomic factors, lifestyle risk factors, and cardiometabolic risk factors (p = 0.007). There were no significant interactions of gender, age, each socioeconomic factor, lifestyle risk factor, and cardiometabolic risk factors on the association between first-degree FHD and the presence of depressive symptoms, respectively (all p > 0.05).

Conclusions

First-degree FHD was associated with depressive symptoms independent of socioeconomic factors, lifestyle risk factors, and cardiometabolic risk factors. Genetic background might mainly contribute to the familial aggregation of depressive symptoms in individuals with first-degree FHD, who should be paid early attention to their mental health.

背景抑郁症和糖尿病的共存是精神-身体合并症的典型例子。本研究旨在探讨糖尿病一级家族史(FHD)与抑郁症状的关系。方法本工作是REACTION研究基线调查的一部分。一级FHD被定义为有一个或多个一级亲属患有糖尿病。采用患者健康问卷-9 (Patient Health Questionnaire-9)检测抑郁症状的存在,且其评分≥5分。进行逻辑回归分析以确定一级FHD与抑郁症状存在之间的关联。结果本研究共纳入4804名受试者。患有一级FHD的个体比没有一级FHD的个体更容易出现抑郁症状(7.2%对4.9%,p = 0.004)。调整性别、年龄、社会经济因素、生活方式危险因素、心脏代谢危险因素后,伴有一级FHD的患者抑郁症状的比值比(OR)增加49.8% (p = 0.007)。性别、年龄、各社会经济因素、生活方式危险因素和心脏代谢危险因素对一级FHD与抑郁症状存在的相关性没有显著的交互作用(p > 0.05)。结论一级FHD与抑郁症状相关,独立于社会经济因素、生活方式危险因素和心脏代谢危险因素。遗传背景可能是一级FHD患者抑郁症状家族聚集的主要原因,应尽早关注其心理健康状况。
{"title":"First-Degree Family History of Diabetes Is Associated With the Presence of Depressive Symptoms Independent of Lifestyle Risk Factors and Cardiometabolic Risk Factors","authors":"Mengying Chen,&nbsp;Huimin Xia,&nbsp;Yaohui Yu,&nbsp;Yuhua Wang,&nbsp;Wei Chen,&nbsp;Enyu Lou,&nbsp;Zhezhe Tang,&nbsp;Lijuan Yang,&nbsp;Shengjie Ge,&nbsp;Bo Yang,&nbsp;Xuejiang Gu,&nbsp;Xiang Hu","doi":"10.1111/1753-0407.70139","DOIUrl":"https://doi.org/10.1111/1753-0407.70139","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Co-occurrence of depression and diabetes is a prototypical example of mental-physical comorbidity. This study aims to investigate the association between first-degree family history of diabetes (FHD) and the presence of depressive symptoms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The present work was one part of the baseline survey from the REACTION study. First-degree FHD was defined as having one or more first-degree relatives with diabetes. The Patient Health Questionnaire-9 was administered to detect the presence of depressive symptoms with its score ≥ 5. Logistic regression analyses were performed to determine the association between first-degree FHD and the presence of depressive symptoms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 4804 participants were enrolled in the present study. Individuals with first-degree FHD were more likely to suffer from depressive symptoms compared with those without first-degree FHD (7.2% versus 4.9%, <i>p</i> = 0.004). The odds ratio (OR) of depressive symptoms was increased by 49.8% with the presence of first-degree FHD after adjustment of gender, age, socioeconomic factors, lifestyle risk factors, and cardiometabolic risk factors (<i>p</i> = 0.007). There were no significant interactions of gender, age, each socioeconomic factor, lifestyle risk factor, and cardiometabolic risk factors on the association between first-degree FHD and the presence of depressive symptoms, respectively (all <i>p</i> &gt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>First-degree FHD was associated with depressive symptoms independent of socioeconomic factors, lifestyle risk factors, and cardiometabolic risk factors. Genetic background might mainly contribute to the familial aggregation of depressive symptoms in individuals with first-degree FHD, who should be paid early attention to their mental health.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 8","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70139","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144861889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends, Social Determinants, and Lifestyle Factors Associated With Comorbidity of Diabetes and Kidney Diseases Among Chinese Adults Aged ≥ 45 Years 中国≥45岁成人糖尿病和肾病共病的趋势、社会决定因素和生活方式因素
IF 3.7 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-08-15 DOI: 10.1111/1753-0407.70142
Guanghui Cui, Shaojie Li, Yu Qin, Yuqin Zhang, Kunpeng Hui, Mengfan Feng, Weiwei Li, Xuezhi Zhang

Objectives

The dual burden of diabetes and kidney disease poses a growing public health challenge in aging populations, yet its longitudinal trends and modifiable determinants in China remain understudied. This study aims to track the trends in the prevalence of the comorbidity of diabetes and kidney disease in Chinese middle-aged and older adults over a 10-year period (2011–2020) and identify social determinants and lifestyle factors associated with this comorbidity.

Methods

This study utilized data from five waves of the China Health and Retirement Longitudinal Study (CHARLS). Temporal trends and geographical distributions of the comorbidity of diabetes and kidney diseases were analyzed across survey years; disaggregated by sex, residence, and geographical region. Cox proportional hazards regression models were employed to explore the associations between SDOH burden, lifestyle factors, and the risk of comorbidity.

Results

The prevalence of diabetes and kidney disease comorbidity exhibited a clear upward trend among Chinese adults aged ≥ 45 years, increasing from 0.60% in 2011 to 3.10% in 2020. Geographical analysis revealed significant regional disparities, with Northeast China having the highest prevalence throughout the decade (4.76% in 2020). High SDOH burden was associated with an increased risk of comorbidity (HR = 1.24, 95% CI = 1.01–1.52). Conversely, maintaining a good (HR = 0.38, 95% CI = 0.27–0.54) or moderate (HR = 0.74, 95% CI = 0.59–0.91) lifestyle was associated with a reduced risk.

Conclusion

The rising prevalence and significant regional disparities of diabetes and kidney disease comorbidity underscore the urgent need for targeted public health interventions in China.

糖尿病和肾脏疾病的双重负担给老龄化人口带来了越来越大的公共卫生挑战,但其在中国的纵向趋势和可改变的决定因素仍未得到充分研究。本研究旨在追踪10年间(2011-2020年)中国中老年人糖尿病和肾脏疾病合并症的流行趋势,并确定与这种合并症相关的社会决定因素和生活方式因素。方法本研究利用中国健康与退休纵向研究(CHARLS)的五波数据。分析了糖尿病和肾脏疾病合并症的时间趋势和地理分布;按性别、居住地和地理区域分列。采用Cox比例风险回归模型探讨SDOH负担、生活方式因素与合并症风险之间的关系。结果中国≥45岁成人糖尿病和肾脏疾病合并症患病率呈明显上升趋势,从2011年的0.60%上升到2020年的3.10%。区域差异显著,东北地区10年患病率最高(2020年为4.76%)。高SDOH负担与合并症风险增加相关(HR = 1.24, 95% CI = 1.01-1.52)。相反,保持良好(HR = 0.38, 95% CI = 0.27-0.54)或适度(HR = 0.74, 95% CI = 0.59-0.91)的生活方式与降低风险相关。结论糖尿病和肾脏疾病合并症患病率的上升和显著的地区差异突出了中国迫切需要有针对性的公共卫生干预措施。
{"title":"Trends, Social Determinants, and Lifestyle Factors Associated With Comorbidity of Diabetes and Kidney Diseases Among Chinese Adults Aged ≥ 45 Years","authors":"Guanghui Cui,&nbsp;Shaojie Li,&nbsp;Yu Qin,&nbsp;Yuqin Zhang,&nbsp;Kunpeng Hui,&nbsp;Mengfan Feng,&nbsp;Weiwei Li,&nbsp;Xuezhi Zhang","doi":"10.1111/1753-0407.70142","DOIUrl":"https://doi.org/10.1111/1753-0407.70142","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The dual burden of diabetes and kidney disease poses a growing public health challenge in aging populations, yet its longitudinal trends and modifiable determinants in China remain understudied. This study aims to track the trends in the prevalence of the comorbidity of diabetes and kidney disease in Chinese middle-aged and older adults over a 10-year period (2011–2020) and identify social determinants and lifestyle factors associated with this comorbidity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study utilized data from five waves of the China Health and Retirement Longitudinal Study (CHARLS). Temporal trends and geographical distributions of the comorbidity of diabetes and kidney diseases were analyzed across survey years; disaggregated by sex, residence, and geographical region. Cox proportional hazards regression models were employed to explore the associations between SDOH burden, lifestyle factors, and the risk of comorbidity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The prevalence of diabetes and kidney disease comorbidity exhibited a clear upward trend among Chinese adults aged ≥ 45 years, increasing from 0.60% in 2011 to 3.10% in 2020. Geographical analysis revealed significant regional disparities, with Northeast China having the highest prevalence throughout the decade (4.76% in 2020). High SDOH burden was associated with an increased risk of comorbidity (HR = 1.24, 95% CI = 1.01–1.52). Conversely, maintaining a good (HR = 0.38, 95% CI = 0.27–0.54) or moderate (HR = 0.74, 95% CI = 0.59–0.91) lifestyle was associated with a reduced risk.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The rising prevalence and significant regional disparities of diabetes and kidney disease comorbidity underscore the urgent need for targeted public health interventions in China.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 8","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70142","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144843667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sleep Phenotypes, Genetic Susceptibility, and Risk of Obesity in Patients With Type 2 Diabetes: A National Prospective Cohort Study: A Commentary 2型糖尿病患者的睡眠表型、遗传易感性和肥胖风险:一项全国前瞻性队列研究:评论
IF 3.7 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-08-15 DOI: 10.1111/1753-0407.70146
Nimra Khan,  Rida-e-Zehra, Nandni Dileep

This commentary discusses the study “Sleep Phenotypes, Genetic Susceptibility, and Risk of Obesity in Patients with Type 2 Diabetes: A National Prospective Cohort Study” by Xi et al. The study provides a perceptive investigation of how metabolic characteristics and genetic variables interact to affect body mass index (BMI) in people with T2D. It has some limitations, including reliance on self-reported sleep data and lack of in-depth sleep quality assessment. We highlight the importance of objective sleep data, detailed assessments of sleep quality, and advanced polygenic risk models in future research to better understand these relationships and inform precision diabetes care.

这篇评论讨论了Xi等人的研究“2型糖尿病患者的睡眠表型、遗传易感性和肥胖风险:一项全国前瞻性队列研究”。该研究对代谢特征和遗传变量如何相互作用影响T2D患者的体重指数(BMI)提供了一个敏锐的调查。它有一些局限性,包括依赖于自我报告的睡眠数据和缺乏深入的睡眠质量评估。我们强调在未来的研究中,客观睡眠数据、详细的睡眠质量评估和先进的多基因风险模型的重要性,以更好地了解这些关系,并为精确的糖尿病护理提供信息。
{"title":"Sleep Phenotypes, Genetic Susceptibility, and Risk of Obesity in Patients With Type 2 Diabetes: A National Prospective Cohort Study: A Commentary","authors":"Nimra Khan,&nbsp; Rida-e-Zehra,&nbsp;Nandni Dileep","doi":"10.1111/1753-0407.70146","DOIUrl":"https://doi.org/10.1111/1753-0407.70146","url":null,"abstract":"<p>This commentary discusses the study “Sleep Phenotypes, Genetic Susceptibility, and Risk of Obesity in Patients with Type 2 Diabetes: A National Prospective Cohort Study” by Xi et al. The study provides a perceptive investigation of how metabolic characteristics and genetic variables interact to affect body mass index (BMI) in people with T2D. It has some limitations, including reliance on self-reported sleep data and lack of in-depth sleep quality assessment. We highlight the importance of objective sleep data, detailed assessments of sleep quality, and advanced polygenic risk models in future research to better understand these relationships and inform precision diabetes care.</p>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 8","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70146","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144853664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stress Hyperglycemia Ratio Outperforms Glycemic Variability in Predicting Mortality Among Acute Myocardial Infarction Patients With Reduced Ejection Fraction: A Retrospective Cohort Study 应激高血糖率优于血糖变异性预测急性心肌梗死患者射血分数降低的死亡率:一项回顾性队列研究
IF 3.7 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-08-13 DOI: 10.1111/1753-0407.70122
Weiyan Lai, Xiu Ying Peng, Hui Peng, Yang Chen

Aims

Stress hyperglycemia ratio (SHR) and glycemic variability (GV) are established markers of glucose metabolism dysregulation. This study compared their predictive values for mortality and arrhythmic events in patients with reduced ejection fraction following acute myocardial infarction (AMI).

Materials and Methods

We analyzed 1933 AMI patients with reduced ejection fraction from the MIMIC-IV database (v3.1, 2008–2022). The primary endpoint was in-hospital mortality, with secondary endpoints including 1-year all-cause mortality, ventricular tachycardia/ventricular fibrillation (VT/VF), and cardiac arrest. Multivariate logistic regression models evaluated associations with in-hospital outcomes, while Cox proportional hazards models assessed 1-year mortality. Restricted cubic spline models examined non-linear relationships between SHR and outcomes, with discriminative ability compared using area under the receiver operating characteristic curve (AUC) analysis.

Results

Among patients (mean age 67.3 years), 401 (20.7%) died during hospitalization and 662 (34.2%) within one year. After adjustment, SHR showed the strongest association with in-hospital mortality (odds ratio [OR]: 1.51, 95% confidence interval [CI]: 1.24–1.82) compared to GV (OR: 1.00, 95% CI: 0.99–1.01). For 1-year mortality, SHR maintained superior performance (hazard ratio: 1.40, 95% CI: 1.19–1.65), with the highest tertile significantly associated with increased risk. ROC analysis confirmed SHR's superior predictive capacity for both mortality endpoints and VT/VF, while none of the indices significantly predicted cardiac arrest. SHR's predictive value was more pronounced in non-diabetic patients.

Conclusions

In post-AMI patients with reduced ejection fraction, SHR demonstrated superior predictive value for mortality compared to GV, supporting its incorporation into risk stratification models for individualized glucose management.

目的应激性高血糖率(SHR)和血糖变异性(GV)是葡萄糖代谢失调的标志。本研究比较了它们对急性心肌梗死(AMI)后射血分数降低患者死亡率和心律失常事件的预测价值。材料和方法我们从MIMIC-IV数据库(v3.1, 2008-2022)中分析了1933例AMI患者的射血分数降低。主要终点是住院死亡率,次要终点包括1年全因死亡率、室性心动过速/心室颤动(VT/VF)和心脏骤停。多变量logistic回归模型评估了与住院预后的关系,而Cox比例风险模型评估了1年死亡率。限制三次样条模型考察了SHR与预后之间的非线性关系,并利用受试者工作特征曲线下的面积(AUC)分析进行了判别能力的比较。结果平均年龄67.3岁,住院期间死亡401例(20.7%),1年内死亡662例(34.2%)。调整后,与GV (OR: 1.00, 95% CI: 0.99-1.01)相比,SHR与住院死亡率的相关性最强(比值比[OR]: 1.51, 95%可信区间[CI]: 1.24-1.82)。对于1年死亡率,SHR保持了优越的表现(风险比:1.40,95% CI: 1.19-1.65),最高的不育率与风险增加显著相关。ROC分析证实SHR对死亡率终点和VT/VF的预测能力均优于其他指标,但没有指标能显著预测心脏骤停。SHR的预测价值在非糖尿病患者中更为明显。结论:在射血分数降低的ami后患者中,SHR对死亡率的预测价值优于GV,支持将其纳入个体化血糖管理的风险分层模型。
{"title":"Stress Hyperglycemia Ratio Outperforms Glycemic Variability in Predicting Mortality Among Acute Myocardial Infarction Patients With Reduced Ejection Fraction: A Retrospective Cohort Study","authors":"Weiyan Lai,&nbsp;Xiu Ying Peng,&nbsp;Hui Peng,&nbsp;Yang Chen","doi":"10.1111/1753-0407.70122","DOIUrl":"https://doi.org/10.1111/1753-0407.70122","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Stress hyperglycemia ratio (SHR) and glycemic variability (GV) are established markers of glucose metabolism dysregulation. This study compared their predictive values for mortality and arrhythmic events in patients with reduced ejection fraction following acute myocardial infarction (AMI).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>We analyzed 1933 AMI patients with reduced ejection fraction from the MIMIC-IV database (v3.1, 2008–2022). The primary endpoint was in-hospital mortality, with secondary endpoints including 1-year all-cause mortality, ventricular tachycardia/ventricular fibrillation (VT/VF), and cardiac arrest. Multivariate logistic regression models evaluated associations with in-hospital outcomes, while Cox proportional hazards models assessed 1-year mortality. Restricted cubic spline models examined non-linear relationships between SHR and outcomes, with discriminative ability compared using area under the receiver operating characteristic curve (AUC) analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among patients (mean age 67.3 years), 401 (20.7%) died during hospitalization and 662 (34.2%) within one year. After adjustment, SHR showed the strongest association with in-hospital mortality (odds ratio [OR]: 1.51, 95% confidence interval [CI]: 1.24–1.82) compared to GV (OR: 1.00, 95% CI: 0.99–1.01). For 1-year mortality, SHR maintained superior performance (hazard ratio: 1.40, 95% CI: 1.19–1.65), with the highest tertile significantly associated with increased risk. ROC analysis confirmed SHR's superior predictive capacity for both mortality endpoints and VT/VF, while none of the indices significantly predicted cardiac arrest. SHR's predictive value was more pronounced in non-diabetic patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In post-AMI patients with reduced ejection fraction, SHR demonstrated superior predictive value for mortality compared to GV, supporting its incorporation into risk stratification models for individualized glucose management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 8","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70122","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144832807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Diabetes
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1